CCND1 and neoplasm: Also consistent with the CGP results [7] is lapatinib’s (row-clade d) sensitivity to tumor cells with ERBB2_MUT (column-clade E), which, according to these results, is also accompanied by MUTs in CCND1, NF2 and SMAD4.